60 Degrees Pharmaceuticals, Inc. (SXTPW) — SEC Filings
60 Degrees Pharmaceuticals, Inc. (SXTPW) — 42 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 26 8-K, 5 10-Q, 3 DEF 14A.
View 60 Degrees Pharmaceuticals, Inc. on SEC EDGAR
Overview
60 Degrees Pharmaceuticals, Inc. (SXTPW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: 60 DEGREES PHARMACEUTICALS, INC. (SXTPW) reported a net loss of $2,317,036 for the three months ended September 30, 2025, compared to a net loss of $2,160,498 for the same period in 2024, representing a 7.2% increase in loss. For the nine months ended September 30, 2025, the net loss was $5,929,267,
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 4 bearish, 38 neutral. The dominant filing sentiment for 60 Degrees Pharmaceuticals, Inc. is neutral.
Filing Type Overview
60 Degrees Pharmaceuticals, Inc. (SXTPW) has filed 5 10-Q, 26 8-K, 3 DEF 14A, 3 S-1, 2 10-K, 1 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of SXTPW's 37 recent filings, 5 were flagged as high-risk, 8 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $437,602 |
| Net Income | -$2,317,036 |
| EPS | N/A |
| Debt-to-Equity | 0.54 |
| Cash Position | $4,115,779 |
| Operating Margin | N/A |
| Total Assets | $6,689,344 |
| Total Debt | $2,487,378 |
Key Executives
- District of Columbia
- Delaware
- Washington, D.C.
- Australia
- Geoffrey Dow
- Tyrone Miller
- Geoffrey S. Dow
- Ross D. Carmel, Esq.
- Rakesh Gopalan
- David S. Wolpa
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external funding to finance operations and clinical trials. Success is driven by innovation, patent protection, and successful commercialization of novel therapies.
Top Tags
8-K (9) · filing (7) · material-agreement (5) · 8-k (5) · pharmaceuticals (5) · corporate-governance (4) · financial-statements (4) · regulatory-filing (4) · financials (4) · corporate-action (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $4,115,779 | as of September 30, 2025, up from $1,659,353 at December 31, 2024 |
| Net Loss (3 months) | $2,317,036 | for the three months ended September 30, 2025, an increase from $2,160,498 in 2024 |
| Net Loss (9 months) | $5,929,267 | for the nine months ended September 30, 2025, a slight increase from $5,906,739 in 2024 |
| Product Revenues (3 months) | $437,602 | for the three months ended September 30, 2025, up 223% from $135,293 in 2024 |
| Research Revenues (3 months) | $90,960 | for the three months ended September 30, 2025, up from $12,818 in 2024 |
| Cost of Revenues (3 months) | $537,690 | for the three months ended September 30, 2025, up from $111,687 in 2024 |
| Gross Loss (3 months) | $100,088 | for the three months ended September 30, 2025, compared to a gross profit of $23,606 in 2024 |
| Accumulated Deficit | $46,454,556 | as of September 30, 2025, indicating significant historical losses |
| Common Stock Shares Outstanding | 4,230,448 | as of November 13, 2025 |
| Reverse Stock Split | 1:5 | effected on February 24, 2025 |
| SEC File Number | 001-41719 | Identifies the company's filing with the SEC. |
| IRS Employer Identification Number | 45-2406880 | Company's tax identification number. |
| Increase in shares for 2022 Equity Incentive Plan | 250,000 shares | Proposed increase in common stock available for issuance |
| Reverse stock split ratio range | 1:3 to 1:10 | Proposed range for reverse stock split of common stock |
| Common stock outstanding | 4,104,469 shares | Total shares of common stock outstanding as of the Record Date, August 26, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for 60 Degrees Pharmaceuticals, Inc. (SXTPW)?
60 Degrees Pharmaceuticals, Inc. has 42 recent SEC filings from Jan 2024 to Nov 2025, including 26 8-K, 5 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SXTPW filings?
Across 42 filings, the sentiment breakdown is: 4 bearish, 38 neutral. The dominant sentiment is neutral.
Where can I find 60 Degrees Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all 60 Degrees Pharmaceuticals, Inc. (SXTPW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for 60 Degrees Pharmaceuticals, Inc.?
Key financial highlights from 60 Degrees Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SXTPW?
The investment thesis for SXTPW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at 60 Degrees Pharmaceuticals, Inc.?
Key executives identified across 60 Degrees Pharmaceuticals, Inc.'s filings include District of Columbia, Delaware, Washington, D.C., Australia, Geoffrey Dow and 5 others.
What are the main risk factors for 60 Degrees Pharmaceuticals, Inc. stock?
Of SXTPW's 37 assessed filings, 5 were flagged high-risk, 8 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from 60 Degrees Pharmaceuticals, Inc.?
Forward guidance and predictions for 60 Degrees Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.